Literature DB >> 33315071

Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review.

Massimo Filippi1,2,3,4, Paolo Preziosa1,2, Frederik Barkhof5,6, Declan T Chard7,8, Nicola De Stefano9, Robert J Fox10, Claudio Gasperini11, Ludwig Kappos12, Xavier Montalban13,14, Bastiaan Moraal5, Daniel S Reich15, Àlex Rovira16, Ahmed T Toosy7, Anthony Traboulsee17,18, Brian G Weinshenker19, Burcu Zeydan19,20, Brenda L Banwell21,22, Maria A Rocca1,2.   

Abstract

Importance: Although magnetic resonance imaging (MRI) is useful for monitoring disease dissemination in space and over time and excluding multiple sclerosis (MS) mimics, there has been less application of MRI to progressive MS, including diagnosing primary progressive (PP) MS and identifying patients with relapsing-remitting (RR) MS who are at risk of developing secondary progressive (SP) MS. This review addresses clinical application of MRI for both diagnosis and prognosis of progressive MS. Observations: Although nonspecific, some spinal cord imaging features (diffuse abnormalities and lesions involving gray matter [GM] and ≥2 white matter columns) are typical of PPMS. In patients with PPMS and those with relapse-onset MS, location of lesions in critical central nervous system regions (spinal cord, infratentorial regions, and GM) and MRI-detected high inflammatory activity in the first years after diagnosis are risk factors for long-term disability and future progressive disease course. These measures are evaluable in clinical practice. In patients with established MS, GM involvement and neurodegeneration are associated with accelerated clinical worsening. Subpial demyelination and slowly expanding lesions are novel indicators of progressive MS. Conclusions and Relevance: Diagnosis of PPMS is more challenging than diagnosis of RRMS. No qualitative clinical, immunological, histopathological, or neuroimaging features differentiate PPMS and SPMS; both are characterized by imaging findings reflecting neurodegeneration and are also impacted by aging and comorbidities. Unmet diagnostic needs include identification of MRI markers capable of distinguishing PPMS from RRMS and predicting the evolution of RRMS to SPMS. Integration of multiple parameters will likely be essential to achieve these aims.

Entities:  

Mesh:

Year:  2021        PMID: 33315071     DOI: 10.1001/jamaneurol.2020.4689

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  8 in total

1.  The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.

Authors:  Elena Di Sabatino; Lorenzo Gaetani; Silvia Sperandei; Andrea Fiacca; Giorgio Guercini; Lucilla Parnetti; Massimiliano Di Filippo
Journal:  J Neurol       Date:  2021-11-24       Impact factor: 4.849

2.  Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers.

Authors:  Monica Margoni; Paolo Preziosa; Paola Tortorella; Massimo Filippi; Maria A Rocca
Journal:  Neurotherapeutics       Date:  2022-06-06       Impact factor: 6.088

3.  Chronic lesion activity and disability progression in secondary progressive multiple sclerosis.

Authors:  Vanessa Beynon; Ilena C George; Colm Elliott; Douglas L Arnold; Jun Ke; Huaihou Chen; Li Zhu; Chunlei Ke; Gavin Giovannoni; Matthew Scaramozza; Nolan Campbell; Daniel P Bradley; Nathalie Franchimont; Arie Gafson; Shibeshih Belachew
Journal:  BMJ Neurol Open       Date:  2022-06-07

4.  Multiple sclerosis lesions and atrophy in the spinal cord: Distribution across vertebral levels and correlation with disability.

Authors:  Matthias Bussas; Malek El Husseini; Laura Harabacz; Viktor Pineker; Sophia Grahl; Viola Pongratz; Achim Berthele; Isabelle Riederer; Claus Zimmer; Bernhard Hemmer; Jan S Kirschke; Mark Mühlau
Journal:  Neuroimage Clin       Date:  2022-04-13       Impact factor: 4.891

Review 5.  Tissue donations for multiple sclerosis research: current state and suggestions for improvement.

Authors:  Patrick Vanderdonckt; Francesca Aloisi; Giancarlo Comi; Alexander de Bruyn; Hans-Peter Hartung; Inge Huitinga; Tanja Kuhlmann; Claudia F Lucchinetti; Imke Metz; Richard Reynolds; Hans Lassmann
Journal:  Brain Commun       Date:  2022-04-19

Review 6.  Magnetic Resonance Imaging in Primary Progressive Multiple Sclerosis Patients : Review.

Authors:  Malgorzata Siger
Journal:  Clin Neuroradiol       Date:  2022-03-08       Impact factor: 3.156

Review 7.  Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective.

Authors:  Giacomo Lus; Marco André Bassano; Vincenzo Brescia Morra; Simona Bonavita; Antonio Gallo; Davide Maimone; Laura Malerba; Giorgia Teresa Maniscalco; Francesco Saccà; Giuseppe Salemi; Renato Turrini; Salvatore Cottone; Edoardo Sessa; Maria Buccafusca; Luigi Maria Edoardo Grimaldi
Journal:  Neurol Sci       Date:  2022-09-17       Impact factor: 3.830

8.  Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.

Authors:  Paolo Preziosa; Elisabetta Pagani; Alessandro Meani; Lucia Moiola; Mariaemma Rodegher; Massimo Filippi; Maria A Rocca
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-02-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.